FDAnews Drug Daily Bulletin

ANIKA THERAPEUTICS ANNOUNCES WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH GALDERMA PHARMA

July 6, 2006
A A

Anika Therapeutics, Inc. today announced that it has signed an exclusive worldwide development and commercialization agreement with Galderma Pharma S.A., a joint venture between Nestle and L'Oreal, for cosmetic tissue augmentation ("CTA") therapies. CTA therapies are used in patients for the correction of facial wrinkles, scar remediation, and lip augmentation.
Pipeline Review